Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosed with PD within a maximum of 3 years prior to screening.~* Has not received levodopa or any other treatment for PD, herein referred to as symptomatic PD medication (including but, not limited to, dopamine agonists, amantadine, anticholinergics, monoamine oxidase type B (MAO-B) inhibitors, or safinamide) for at least 12 weeks prior to Day 1. Maximum total duration of prior PD regimens should not exceed 30 days.~* Score of less than equal to (\<=) 2.5 on the Modified Hoehn and Yahr Scale.~* Screening dopamine transporter (DaT)/ single-photon emission computed tomography (SPECT) results consistent with neurodegenerative Parkinsonism (central reader).~Key Exclusion Criteria:~* Presence of freezing of gait.~* History of or positive test result at Screening for human immunodeficiency virus (HIV) or hepatitis C virus antibody (anti-HCV).~* Screening value for hemoglobin less than (\<)12 gram per deciliter (g/dL) for men or \<11 g/dL for women.~* Montreal Cognitive Assessment (MoCA) score \<23 or other significant cognitive impairment or clinical dementia.~* History of any brain surgery for PD.~* Participation in any passive or active immunotherapy targeting alpha-synuclein or other PD-related protein.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: BIIB054 Dose A (Type: EXPERIMENTAL): Participants will receive IV infusion of BIIB054 Dose A (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
- Cohort 2: BIIB054 Dose B (Type: EXPERIMENTAL): Participants will receive IV infusion of BIIB054 Dose B (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
- Cohort 3: BIIB054 Dose C (Type: EXPERIMENTAL): Participants will receive IV infusion of BIIB054 Dose C (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
- Cohorts 1-3: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive a single IV infusion of BIIB054 matching placebo (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).